Biotech Values

[dav1234]

FDA confirms lifting of clinical hold on Oxygen Bio's Oxycyte
Oxygen Biotherapeutics (OXBT) has received written confirmation that the FDA has lifted a hold on the clinical trials of the company's Oxycyte treatment for traumatic brain injury.
The FDA had informed Oxygen Bio of its decision verbally earlier this month.
Oxygen has been enrolling patients in Israel for a Phase IIb study to evaluate the safety and tolerability of Oxycyte in patients with severe non-penetrating traumatic brain injury.
Shares jump 10.6% premarket
http://seekingalpha.com/pr/9414453-oxygen-biotherapeutics-inc-provides-an-update-on-communication-with-the-fda-regarding-oxycyte-development-program